1. (1) Fine MJ, Orloff JJ, Arisumi D, Fang GD, Arena VC, Hanusa BH, et al. Prognosis of patients hospitalized with community-acquired pneumonia. Am J Med [Internet]. 1990;88(5N):1N-8N. Available from: https://pubmed.ncbi.nlm.nih.gov/2195886/
2. (2) Auble TE, Yealy DM, Fine MJ. Assessing prognosis and selecting an initial site of care for adults with community-acquired pneumonia. Infect Dis Clin North Am [Internet]. 1998;12(3):741-59, x. https://doi.org/10.1016/S0891-5520(05)70208-7
3. (3) Metlay JP, Waterer GW, Long AC, Anzueto A, Brozek J, Crothers K, et al. Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med [Internet]. 2019;200(7):e45-e67. https://doi.org/10.1164/rccm.201908-1581ST
4. (4) Kirchhof P, Toennis T, Goette A, Camm AJ, Diener HC, Becher N, et al. Anticoagulation with Edoxaban in Patients with Atrial High-Rate Episodes. N Engl J Med [Internet]. 2023;389(13):1167-79. https://doi.org/10.1056/NEJMoa2303062
5. (5) Healey JS, Lopes RD, Granger CB, Alings M, Rivard L, McIntyre WF, et al. Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation. N Engl J Med [Internet]. 2024;390(2):107-17. https://doi.org/10.1056/NEJMoa2310234